Navigation Links
Toward explaining why hepatitis B hits men harder than women
Date:11/18/2009

Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Their study has been published online in ACS' Journal of Proteome Research, a monthly publication.

Shuhan Sun, Fang Wang and colleagues note that chronic hepatitis B seems to progress and cause liver damage faster in men, with men the main victims of the virus's most serious complications -- cirrhosis and liver cancer. Men infected with HBV also are 6 times more likely than women to develop a chronic form of the disease. About 400 million people worldwide have chronic hepatitis B, including a form that is highly infectious and can be transmitted through blood, saliva, and sexual contact.

In experiments with laboratory mice, the scientists found abnormal forms of apolipoprotein A-I (Apo A-I), a protein involved in fighting inflammation, in the livers of infected male mice but not infected females. They then identified abnormal forms of these Apo A-I proteins in blood of men infected with HBV, but not in women. In addition to explaining the gender differences, the proteins may provide important markers for tracking the progression of hepatitis B, the scientists suggest.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert  

4

GOOD

Page: 1

Related biology news :

1. Toward bold new anti-cancer medicines
2. Scientists take step toward simple and portable tuberculosis tests for developing world
3. A step toward better brain implants using conducting polymer nanotubes
4. Toward a nanomedicine for brain cancer
5. Rats move toward the food but do not eat
6. Scientists take early steps toward mapping epigenetic variability
7. Toward an explanation for Crohns disease?
8. Gene expression findings a step toward better classification and treatment of juvenile arthritis
9. Toward cheap underwater sensor nets
10. Activated stem cells in damaged lungs could be first step toward cancer
11. Progress toward artificial tissue?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Toward explaining why hepatitis B hits men harder than women
Toward explaining why hepatitis B hits men harder than women
(Date:2/9/2010)... Miami have analyzed images based on Synthetic Aperture ... Haiti,s earthquake, on January 12. The images reveal ... using data from Japan,s ALOS satellite and made ... of the European Space Agency (ESA) and GEO, ... of countries that promotes the exchange of satellite ...
(Date:2/9/2010)... People with anorexia nervosa, paradoxically, have strikingly high levels ... Children,s Hospital Boston. Their findings, based on MRI imaging ... 20 healthy girls of the same age, appear in ... and Mineral Research . , "It,s counter-intuitive that an ... be storing fat in her marrow," says endocrinologist Catherine ...
(Date:2/9/2010)... The Scripps Research Institute have discovered a potential new ... for sheep and cattle infected with liver fluke. The ... in combating river blindness, a tropical disease that is ... humans. , The study is scheduled for publication ... Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):New international satellite observations help assess future earthquake risk in Haiti 2Anorexics found to have excess fat-- in their bone marrow 2Scripps research team reveals how an old drug could have a new use for treating river blindness 2Scripps research team reveals how an old drug could have a new use for treating river blindness 3Scripps research team reveals how an old drug could have a new use for treating river blindness 4GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 1GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 2GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 3GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 4New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 1New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 2New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 3New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 4Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 1Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 2
... prevent global warming, researchers and policymakers are exploring a ... carbon dioxide that reaches the atmosphere. One possible approach ... the source an electric power plant, for example ... theoretically promising, the technique has never been tested in ...
... or array that can quickly detect disorders such as Down ... effective tool in prenatal diagnosis in a series of 300 ... report that appears in the current issue of the journal ... led by Dr. Arthur Beaudet and Dr. Sau Wai Cheung ...
... properties of cancer cells are their ability to divide without ... establish new tumor sites. Now, researchers from the Mayo ... acts as a deadly master switch, both freeing cancer cells ... is potentially good news, say the researchers, who published their ...
Other Biology News:MIT: Safe storage of greenhouse-gas carbon dioxide 2Microarray analysis improves prenatal diagnosis 2Microarray analysis improves prenatal diagnosis 3Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth 2Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth 3
(Date:2/9/2010)... endpoint Clinical ( www.endpointclinical.com ), a ... (IWR) systems, announced today that PULSE, a fully ... deploy clinical trial Integrated Response Technology (IRT) systems, ... clinical trials. This time and cost savings stems ... developers do not have to spend valuable time ...
(Date:2/9/2010)... A leading clinical research center in ... study an investigational drug designed as a possible treatment ... affects between 45 and 90 percent of women of ... not life threatening, dysmenorrhea can be debilitating and psychologically ... absenteeism from work and school. ,, Current therapies for ...
(Date:2/9/2010)... BEACH, California and AMSTERDAM , ... in molecular cancer diagnostics, announced today that,it has ... New York State ,Department of Health. The ... to receive,commercial samples of MammaPrint, its FDA-cleared breast ... this latest permit, Agendia has now obtained all ...
(Date:2/9/2010)... February 9 ,, ... Microplasmin to Improve the Treatment,of a Range of ... ThromboGenics NV (Euronext Brussels: THR), a ... innovative treatments for eye,disease, vascular disease and cancer, ... results, evaluating the product,s efficacy and,safety in patients ...
Breaking Biology Technology:endpoint Saves Money and Time for Medical Research Teams Through PULSE 2endpoint Saves Money and Time for Medical Research Teams Through PULSE 3Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps 2Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4
... Training Center Scheduled to Open Friday, Feb. 29, ... Institute, LLC,will open its first training center in the ... local communities. Located in,Milipitas, CA, the center will be ... than 20 million Americans and costs the economy,$174 billion ...
... Continued year over year growth driven by Loestrin 24 ... Warner Chilcott,Limited (Nasdaq: WCRX ) today announced ... 2007. Revenue in the quarter ended December 31, 2007,totaled ... year quarter.,Revenue for the year ended December 31, 2007 ...
... today announced the submission of a supplemental New ... Administration (FDA) for once- daily,SEROQUEL XR(TM) (quetiapine fumarate) ... major depressive disorder (MDD) as,monotherapy, adjunct therapy, and ... 15 million American adults -- between 5 and ...
Other Biology Technology:MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 17AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 8
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Biology Products: